Seek Returns

ILMN vs. VTRS: Illumina vs. Viatris Stock Comparison

How do Illumina (ILMN) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Illumina (ILMN) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ILMN is classified in Life Sciences Tools & Services while VTRS is classified in Pharmaceuticals.

Company profile comparison for Illumina (ILMN) and Viatris (VTRS)
Profile ItemILMNVTRS
NameIllumina Inc.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization32.23 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 28, 2000March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ILMN
VTRS
GSPC
Loading price history…
Illumina (ILMN) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Illumina (ILMN) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Illumina (ILMN) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Total Return (1Y)79.70%108.98%
Total Return (3Y, Annualized)28.16%36.75%
Total Return (5Y, Annualized)-10.65%11.59%

Risk Profile

Drawdown History

ILMN
VTRS
GSPC
Loading price history…
Illumina (ILMN) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Illumina (ILMN) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Volatility (1Y, Annualized)48.47%32.53%
Beta (5Y)1.460.86
Max Drawdown (5Y)-82.95%-45.69%
Avg. Volume (3M)2.77M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ILMN and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Sharpe Ratio (1Y)1.563.22
Sortino Ratio (1Y)2.255.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Illumina (ILMN) reports 32.39%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.39%

Max
109.18%
ILMN
32.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Illumina (ILMN) reports 19.72%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.72%

ILMN
19.72%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Illumina (ILMN) at 20.02% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
83.12%
ILMN
20.02%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
ROE (TTM)32.39%-4.21%
ROA (TTM)8.32%2.91%
Net Margin (TTM)19.72%-4.13%
Operating Margin (TTM)20.02%13.85%
Gross Margin (TTM)67.68%41.13%

Growth

Revenue Growth

Both Illumina (ILMN) at -0.66% and Viatris (VTRS) at -2.98% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Illumina (ILMN) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Revenue Growth (YoY)-0.66%-2.98%
Revenue Growth (3Y CAGR)-1.78%-4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
25.13
Q3
12.13
Median
5.52
ILMN
2.63
Q1
2.47
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Illumina (ILMN) at 0.74 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.74

Max
1.42
ILMN
0.74
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Current Ratio (MRQ)2.631.55
Debt / Equity (MRQ)0.740.99
Net Debt / EBITDA0.852.64

Dividends

Dividend Yield (TTM)

Illumina (ILMN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Illumina (ILMN) pays no dividend (payout 0.00%).

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ILMN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Illumina (ILMN) trades at 36.68 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.68

Max
85.34
Q3
43.46
ILMN
36.68
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; ILMN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Illumina (ILMN) at 7.10 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.10

Max
58.18
Q3
25.77
Median
7.30
ILMN
7.10
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Illumina (ILMN) at 10.30 carries a premium in the upper quartile — a clear price-to-book gap.

ILMN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.30

Max
13.53
ILMN
10.30
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Illumina (ILMN) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Illumina (ILMN) and Viatris (VTRS)
MetricILMNVTRS
P/E Ratio (TTM)36.68--
P/S Ratio (TTM)7.101.55
P/B Ratio (MRQ)10.301.67
Free Cash Flow Yield (TTM)2.67%13.84%